Last reviewed · How we verify
cyclo, vcr, pred, dacarb,etop and doxo
Cyclophosphamide is an alkylating agent that interferes with DNA replication, causing cell death in rapidly dividing cells.
Cyclophosphamide is an alkylating agent that interferes with DNA replication, causing cell death in rapidly dividing cells. Used for Multiple myeloma, Lymphoma, Leukemia.
At a glance
| Generic name | cyclo, vcr, pred, dacarb,etop and doxo |
|---|---|
| Also known as | CYC, VCR, PRED, DTIC, ETO, DOXO |
| Sponsor | University of Giessen |
| Drug class | Alkylating agent |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Cyclophosphamide works by attaching an alkyl group to the DNA of cancer cells, which interferes with their ability to replicate and causes cell death. This leads to a reduction in the number of cancer cells in the body. The exact mechanism of action is not fully understood, but it is thought to involve the formation of DNA cross-links and the activation of various cellular pathways that lead to cell death.
Approved indications
- Multiple myeloma
- Lymphoma
- Leukemia
Common side effects
- Myelosuppression
- Nausea and vomiting
- Hair loss
- Infection
- Bleeding
Key clinical trials
- Second International Inter-Group Study for Classical Hodgkin Lymphoma in Children and Adolescents (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- cyclo, vcr, pred, dacarb,etop and doxo CI brief — competitive landscape report
- cyclo, vcr, pred, dacarb,etop and doxo updates RSS · CI watch RSS
- University of Giessen portfolio CI